Zymeworks Inc
ZYMEHealthcare|Biotechnology|USA
$25.88
-1.19 (-4.40%)
Tangible Book
$2.04
About
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Stock Price
+89.5%(1Y)
Pipeline Summary
7 total trials4
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
Recruiting: 3Active: 1Completed: 2Terminated: 1
Active Trials (4)
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT05035836Breast Cancer
Phase 2Recruiting
Enrollment: 20 participants
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Phase 1Active
Enrollment: 145 participants
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma
Phase 1Recruiting
Enrollment: 100 participants
Personalized Medicine for Advanced Biliary Cancer Patients
NCT05615818Biliary Tract Neoplasms
Phase 3Recruiting
Enrollment: 800 participants
BioScore
5/10
Watchlist
Ownership
Recent Insider Trades
Galbraith KennethSELL
2026-01-1230,424 shares @ $22.67
Smith Jeffrey T LSELL
2026-01-129,310 shares @ $22.67
Hollywood MarkSELL
2026-01-126,120 shares @ $22.67
Moore Paul AndrewSELL
2026-01-129,560 shares @ $22.67
Smith Jeffrey T LSELL
2026-01-0510,538 shares @ $25.1
Recent News
2026-07-07 13:08:05
2026-06-30 15:01:37
2026-06-29 18:00:12
2026-06-29 10:56:52
2026-06-18 13:00:05
Data last updated: Jul 13, 2026, 12:44 PM